# Serina Therapeutics Inc. (SER)

Source: https://www.quantisnow.com/company/SER
Generated: 2026-11-07T22:01:51.894Z

- Ticker: SER
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001708599

## Latest SER news and filings

- 2026-11-03 20:44 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-serina-therapeutics-inc-6769289)
- 2026-10-09 21:19 UTC [SEC Form 8-K] [SEC Form 8-K filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-serina-therapeutics-inc-6743236)
- 2026-09-23 20:18 UTC [Conference Announcement] [Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"](https://www.quantisnow.com/insight/registration-is-now-open-for-tribe-publics-ceo-presentation-and-6724219)
- 2026-09-10 20:05 UTC [Conference Announcement] [Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/serina-therapeutics-to-present-at-the-hc-wainwright-28th-annual-6711511)
- 2026-09-09 11:45 UTC [Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2](https://www.quantisnow.com/insight/serina-therapeutics-reports-cohort-1-observations-from-ser-252-registrational-study-6709259)
- 2026-09-09 11:43 UTC [SEC Form 8-K] [Serina Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/serina-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6709258)
- 2026-09-01 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-serina-therapeutics-inc-6700359)
- 2026-08-24 21:24 UTC [SEC Form S-1] [SEC Form S-1 filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-serina-therapeutics-inc-6693132)
- 2026-08-13 21:00 UTC [SEC Form S-8] [SEC Form S-8 filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-serina-therapeutics-inc-6681135)
- 2026-08-13 20:15 UTC [Leadership Update] [Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/serina-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6680577)
- 2026-08-13 20:05 UTC [SEC Form 8-K] [Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/serina-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6680372)
- 2026-08-13 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-serina-therapeutics-inc-6680176)
- 2026-07-24 10:00 UTC [Conference Announcement] [Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference](https://www.quantisnow.com/insight/serina-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-6647674)
- 2026-07-23 22:52 UTC [SEC Form 4] [SEC Form 4 filed by Director Simon Farrell](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-simon-farrell-6647611)
- 2026-07-23 22:49 UTC [SEC Form 3] [SEC Form 3 filed by new insider Simon Farrell](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-simon-farrell-6647607)
- 2026-07-23 20:51 UTC [SEC Form 8-K] [Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/serina-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6647403)
- 2026-07-23 10:00 UTC [Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease](https://www.quantisnow.com/insight/serina-therapeutics-announces-completion-of-enrollment-and-dosing-in-cohort-6645919)
- 2026-07-22 21:03 UTC [SEC Form 8-K] [Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/serina-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6645669)
- 2026-07-22 20:30 UTC [Leadership Update] [Serina Therapeutics Appoints Farrell Simon to its Board of Directors](https://www.quantisnow.com/insight/serina-therapeutics-appoints-farrell-simon-to-its-board-of-directors-6645466)
- 2026-07-09 16:10 UTC [Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease](https://www.quantisnow.com/insight/serina-therapeutics-announces-completion-of-sentinel-dosing-in-cohort-1-6632788)
- 2026-07-09 16:05 UTC [Insider Buy] [Director Brannan Stephen K. bought $2,030 worth of shares (1,000 units at $2.03) (SEC Form 4)](https://www.quantisnow.com/insight/director-brannan-stephen-k-bought-2030-worth-of-shares-1000-6632785)
- 2026-07-01 12:31 UTC [Analyst Coverage Initiated] [BTIG Research initiated coverage on Serina Therapeutics with a new price target](https://www.quantisnow.com/insight/btig-research-initiated-coverage-on-serina-therapeutics-with-a-new-6622066)
- 2026-06-30 13:01 UTC [Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program](https://www.quantisnow.com/insight/gannet-biochem-and-serina-therapeutics-enter-development-partnership-supporting-ser-252-6620274)
- 2026-06-24 20:10 UTC [SEC Form 8-K] [Serina Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/serina-therapeutics-inc-filed-sec-form-8-k-amendments-to-articles-6614190)
- 2026-06-22 23:15 UTC [Insider Buy] [Director Venkatesan Jay bought $1,048 worth of shares (589 units at $1.78) and converted options into 224,152 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-venkatesan-jay-bought-1048-worth-of-shares-589-units-6611391)
- 2026-06-22 23:14 UTC [SEC Form 4] [Director Bailey Gregory converted options into 8,437,472 shares, increasing direct ownership by 6,663% to 8,564,382 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bailey-gregory-converted-options-into-8437472-shares-increasing-direct-6611389)
- 2026-06-22 23:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Brannan Stephen K.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-brannan-stephen-k-6611387)
- 2026-06-22 23:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Wilson Karen J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wilson-karen-j-6611386)
- 2026-06-22 23:12 UTC [SEC Form 4] [SEC Form 4 filed by Director Marshall Richard Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-marshall-richard-peter-6611385)
- 2026-06-15 14:31 UTC [Insider Buy] [Director Wilson Karen J bought $17,750 worth of shares (10,100 units at $1.76) (SEC Form 4)](https://www.quantisnow.com/insight/director-wilson-karen-j-bought-17750-worth-of-shares-10100-6602188)
- 2026-06-04 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-serina-therapeutics-inc-6588385)
- 2026-05-27 19:55 UTC [SEC Form 4] [Chief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ledger-steven-a-was-granted-10100-shares-6574542)
- 2026-05-26 23:44 UTC [SEC Form 4] [SEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-cmc-formulation-tenjarla-srini-6573426)
- 2026-05-26 23:37 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Ledger Steven A](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-ledger-steven-6573420)
- 2026-05-26 23:35 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Curhan Gregory S](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-curhan-gregory-6573417)
- 2026-05-26 23:33 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Moreadith Randall](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-moreadith-randall-6573411)
- 2026-05-26 20:26 UTC [Insider Buy] [Director Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)](https://www.quantisnow.com/insight/director-wilson-karen-j-bought-37000-worth-of-shares-20000-6572502)
- 2026-05-22 20:59 UTC [Insider Buy] [Director Marshall Richard Peter bought $20,102 worth of shares (12,183 units at $1.65) (SEC Form 4)](https://www.quantisnow.com/insight/director-marshall-richard-peter-bought-20102-worth-of-shares-12183-6570384)
- 2026-05-22 20:00 UTC [SEC Form S-3] [SEC Form S-3 filed by Serina Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-serina-therapeutics-inc-6569460)
- 2026-05-14 20:20 UTC [Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/serina-therapeutics-reports-first-quarter-2026-financial-results-and-provides-6554208)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SER
- Earnings history: https://www.quantisnow.com/earnings/SER
- Dividend history: https://www.quantisnow.com/dividends/SER
- Insider transactions: https://www.quantisnow.com/insiders/SER
- Options chain: https://www.quantisnow.com/options/SER
- SEC 8-K filings only: https://www.quantisnow.com/company/SER/8-k
- RSS and alerts for SER: https://www.quantisnow.com/docs/rss-feeds.md